AbbVie Inc (ABBV)vsXWELL Inc. (XWEL)
ABBV
AbbVie Inc
$294.89
+1.41%
HEALTHCARE · Cap: $521.11B
XWEL
XWELL Inc.
$0.69
-0.03%
HEALTHCARE · Cap: $6.81M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 233313% more annual revenue ($66.01B vs $28.28M). ABBV leads profitability with a 15.7% profit margin vs -82.9%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
XWEL
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$294.89
$138.05 premium
Margin of Safety
+49.5%
Fair Value
$0.78
Current Price
$0.69
$0.09 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -333.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : XWEL
The strongest argument for XWEL centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : XWEL
The primary concerns for XWEL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while XWEL is a turnaround play — different risk/reward profiles.
XWEL carries more volatility with a beta of 0.94 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 21/100), backed by strong 15.7% margins and 10.3% revenue growth. XWEL offers better value entry with a 49.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
XWELL Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?